First Trust Advisors
BCRX icon

First Trust Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

First Trust Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
1,120,469
+319,569
+40% +$2.89M 0.01% 1170
2026
Q1 		$7.62M Buy
800,900
+425,939
+114% +$3.31M 0.01% 1231
2025
Q4 		$2.92M Sell
374,961
-360,026
-49% -$2.6M ﹤0.01% 1703
2025
Q3 		$5.58M Buy
734,987
+7,517
+1% +$62.6K ﹤0.01% 1329
2025
Q2 		$6.52M Buy
727,470
+241,988
+50% +$2.25M 0.01% 1237
2025
Q1 		$3.64M Sell
485,482
-79,733
-14% -$643K ﹤0.01% 1487
2024
Q4 		$4.25M Sell
565,215
-28,251
-5% -$214K ﹤0.01% 1454
2024
Q3 		$4.51M Buy
+593,466
New +$4.51M ﹤0.01% 1382
2024
Q2 		– Sell
-141,387
Closed -$718K – 2321
2024
Q1 		$718K Sell
141,387
-19,337
-12% -$109K ﹤0.01% 2064
2023
Q4 		$963K Buy
+160,724
New +$931K ﹤0.01% 1977
2023
Q3 		– Sell
-176,763
Closed -$1.24M – 2359
2023
Q2 		$1.24M Buy
176,763
+13,600
+8% +$109K ﹤0.01% 1916
2023
Q1 		$1.36M Sell
163,163
-40,471
-20% -$390K ﹤0.01% 1858
2022
Q4 		$2.34M Buy
203,634
+78,566
+63% +$980K ﹤0.01% 1628
2022
Q3 		$1.58M Sell
125,068
-159,783
-56% -$2.06M ﹤0.01% 1805
2022
Q2 		$3.01M Buy
284,851
+109,834
+63% +$1.13M ﹤0.01% 1544
2022
Q1 		$2.85M Sell
175,017
-130,734
-43% -$2.1M ﹤0.01% 1631
2021
Q4 		$4.24M Buy
305,751
+59,305
+24% +$785K ﹤0.01% 1444
2021
Q3 		$3.54M Sell
246,446
-100,387
-29% -$1.58M ﹤0.01% 1520
2021
Q2 		$5.48M Buy
+346,833
New +$4.71M 0.01% 1294
2019
Q3 		– Sell
-49,667
Closed -$188K – 2397
2019
Q2 		$188K Buy
+49,667
New +$299K ﹤0.01% 2363

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

First Trust Advisors's BCRX Position: Q2 2026 in Review

First Trust Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 40% in Q2 2026, buying an estimated $2.89M and bringing the position to 1,120,469 shares worth $11.2M. The position accounts for 0.01% of the portfolio, ranked #1170.

First Trust Advisors first reported a position in BCRX in Q2 2019 and has held it in 20 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • First Trust Advisors held 1,120,469 shares of BioCryst Pharmaceuticals worth $11.2M as of Q2 2026.
  • First Trust Advisors bought 319,569 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.89M.
  • BioCryst Pharmaceuticals made up 0.01% of First Trust Advisors's portfolio in Q2 2026, its #1170 holding.
  • First Trust Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2019 and has held it in 20 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.